3SBio Proposes Spinoff, Hong Kong Listing of Unit Mandi

MT Newswires Live11-21

3SBio (HKG:1530) plans to spin off its consumer pharmaceuticals unit Mandi and seek a separate listing on the Hong Kong Stock Exchange, according to a Thursday bourse filing.

Shares of the biopharmaceutical firm were down nearly 8% in Friday morning trade.

The spinoff will be carried out through a distribution in specie of all Mandi shares held by 3SBio to its shareholders, together with a global offering of new Mandi shares.

After completion, 3SBio will cease to hold any interest in Mandi.

Mandi filed its listing application on Nov. 20, the filing said.

3SBio owns 87.16% of Mandi, which focuses on skin health and weight management products and is known for its Mandi-branded minoxidil hair-loss treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment